Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

CLXC Cagrilinitide 10MG

Cagrilinitide

Cagrilintide is a long-acting synthetic peptide analog of human amylin, developed for use in scientific research focused on metabolic signaling, appetite regulation, and peptide–receptor interactions. As an engineered amylin receptor agonist, Cagrilintide is utilized in controlled laboratory settings to study amylin-mediated pathways involved in satiety signaling, energy balance, and neuroendocrine communication.*

Structurally modified to enhance stability and prolong biological activity compared to native amylin, Cagrilintide serves as a valuable research tool for investigating sustained peptide signaling and receptor engagement within metabolic and endocrine research models.*

  • Peptide Name: Cagrilintide
  • Peptide Class: Long-acting amylin analog
  • Amino Acid Length: 37 amino acids (modified)
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Quantity: Supplied per vial (research format)
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)

$155.00

$147.25 each
$139.50 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

Cagrilinitide

Scientific & Research Context

In published scientific literature, amylin and amylin analogs have been extensively studied for their role in central and peripheral metabolic signaling, particularly within the hypothalamus and brainstem.* Cagrilintide, as a next-generation amylin analog, has been examined in experimental systems designed to explore prolonged receptor activation, peptide pharmacodynamics, and interactions between amylin, incretin, and energy-regulating pathways.*

Within research environments, Cagrilintide has been utilized to investigate:*

  • Amylin receptor signaling and satiety-related pathways*
  • Peptide modulation of appetite and energy balance mechanisms*
  • Structure–activity relationships of long-acting metabolic peptides*
  • Neuroendocrine communication between peripheral peptides and the CNS*
  • Combination peptide signaling models in metabolic research*

Its extended stability and well-characterized molecular structure make Cagrilintide particularly suitable for studies requiring sustained peptide exposure and reproducible receptor engagement.*

Quality & Analytical Assurance

Each batch of Cagrilintide is produced using validated solid-phase peptide synthesis techniques and undergoes comprehensive analytical testing. Verification by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) confirms molecular identity, sequence integrity, and purity, ensuring batch-to-batch consistency for reliable research outcomes.

Storage & Handling

Cagrilintide is supplied in lyophilized form to maintain stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow standard laboratory peptide protocols to preserve molecular integrity and minimize degradation.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Lau, J., Bloch, P., Schäffer, L., et al. “Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.” J. Med. Chem., 2015.
  • Gydesen, S., Andreassen, K. V., Hjuler, S. T., et al. “Amylin analogues and their role in metabolic regulation.” Diabetes Obes. Metab., 2017.
  • van Can, J., Sloth, B., Jensen, C. B., Flint, A. “Effects of the amylin analogue pramlintide on appetite and energy intake.” Diabetes Care, 2014.
  • Mack, C. M., Wilson, J. K., Athanacio, J. R., et al. “Pharmacological actions of long-acting amylin receptor agonists.” Endocrinology, 2010.
  • Roth, J. D., Erickson, M. R., Chen, S., Parkes, D. G. “GLP-1 and amylin agonism in metabolic research models.” Peptides, 2012.
  • Hayes, M. R., Kanoski, S. E., De Jonghe, B. C., et al. “The role of amylin in the control of feeding.” Physiol. Behav., 2011.
  • Larsen, P. J., Knudsen, L. B., & Vrang, N. “Amylin receptor signaling and appetite regulation.” Trends Endocrinol. Metab., 2010.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.